148
sclerosis, presence or absence of subperiosteal bone formation,
sequestra, the visibility of the mandibular canal, cortical border
were scored. Differences between outcomes of denosumab-related
osteonecrosis (DRONJ) of the jaw and BRONJ patients were stud-
ied.
Findings:
In denosumab cases predominantly sclerosis was seen.
Bisphosphonates more sclerosis depending on the duration of the
use or the potency of the bisphosphonates. Sequestra were rare
with denosumab necrosis compared to bisphosphonate necrosis.
Subperiosteal bone formation was predominantly seen in patients
using bisphosphonates. Prominent lamina dura, the visibility of the
mandibular canal and cortical border were seen in both denosumab
and bisphosphonates.
Conclusions:
This study shows a difference in radiological
aspects between denosumab and bisphosphonate cases. In deno-
sumab a sclerosis is seen which is visible only in long-term
bisphosphonate cases. Sequestra were rare in denosumab. These
effects are possibly caused by a difference in the remaining func-
tioning amount of osteoclasts. Further research is mandatory.
http://dx.doi.org/10.1016/j.ijom.2017.02.510Surgical treatment of a cohort of 150 patients with stage
II/III medication-related osteonecrosis of the jaw
S.E.C. Pichardo
∗
, J.P.R. van Merkesteyn
Leiden University Medical Center, The Netherlands
Background:
A side effect of antiresorptive medication
such as bisphosphonates and denosumab is medication-related
osteonecrosis of the jaw (MRONJ). This can be difficult to treat.
Objectives:
The aim of this study was to evaluate the surgical
treatment protocol used in our hospital for MRONJ patients. The
patients were analysed and followed at the Leiden University
Medical Center.
Methods:
150 patients who were seen with therapy-resistant
MRONJ between 2003 and 2016 were analysed. Clinical features,
medical and dental history, antiresorptive use, and the use of other
medications were recorded. The thorough surgical intervention
was combined with antimicrobial treatment and only performed
by senior surgeons, following the principles of our previously
reported protocol.
Findings:
125 patients were surgically treated and followed for
6–105 months with a mean of 18 months. The surgical approach
was successful in 92% of the patients.
Conclusion:
More than 90% of the patients were cured with our
surgical protocol. We conclude that this combined antimicrobial
and surgical treatment protocol has a high success rate in all stages
of MRONJ.
http://dx.doi.org/10.1016/j.ijom.2017.02.511Study on outcomes of oral squamous cell carcinoma after
treatment for two years follow-up at Bangabandhu Sheikh
Mujib Medical University
M.S. Rahman
∗
, A.F.M.S. Rahman
Bangabandhu Sheikh Mujib Medical University, Dhaka,
Bangladesh
Objective:
To evaluate the treatment outcome of oral squamous
cell carcinoma patients by routine follow-up visit and by this
efficacy of institutional management.
Methods:
In the study 56 patients, aged 26–75 years treated
at BSMMU for squamous cell carcinoma of oral cavity were
included. Patients were treated by different modality such
as surgery with incomplete/delayed/no radiotherapy (32.14%),
surgery with radiotherapy (53.57%), surgery with concomi-
tant radiochemotherapy (10.71%) and neoadjuvant therapy then
surgery and adjuvant therapy (3.57%). By routine follow-up,
suspected new tumour growth was determined and fine-needle
aspiration cytology and histopathologywas done. Residual tumour
growth, local recurrence, lymph node metastasis and second pri-
mary tumour growth were detected and by this overall outcome
measured.
Results:
The majority of patients were female and the male to
female ratio was 1:1.4. Tumours of different sites of oral cavity
were treated of which stage I, 23.21%; stage II, 62.5%; stage III,
14.21%; and stage IV patients were not included. Overall out-
come of treatment was 50.0% for two years follow-up. Residual
tumour growth was 9.09%, local recurrence was 36.36%, lymph
nodemetastasis was 2.27%and second primary tumour was 2.27%
within two years. Outcome for two years in stage I 100%, in stage
II 43.3% and in stage III 28.5%. Statistical analysis with SPSS
version 10 showed
P
value for one-year follow-up.
Conclusion:
Our results suggest that to evaluate the treatment
outcome routine follow-up is necessary. Also efficacy and failure
of treatment can be measured.
http://dx.doi.org/10.1016/j.ijom.2017.02.512Bisphosphonate-related osteonecrosis of the jaws: our
experience in up to 120 cases
C.E.X.S. Ribeiro da Silva
∗
, A.C. Rodriguez, D.M. Costa,
M. Martins, V. Oliveira, R. Murad Neto
Instituto de Ensino, Pesquisa e Difusão Prevent Senior, Brazil
Osteonecrosis of the jaw has been related to the use of bisphospho-
nates for more than a decade, with numerous attempts of different
treatments and even the presentation protocols by surgeons asso-
ciations. We aim to present a series of clinical cases with various
complexities, presenting forms of treatment adopted by our ser-
vice. We collected clinical data from 120 patients, considering
the type of bisphosphonate treatment, time of use, location and
extent of osteonecrosis and the treatment performed in our hos-
pital. We have adopted the protocol to perform surgical removal
of necrosis, associated with pentoxifylline and tocopherol, and
hyperbaric chamber therapy for indicated cases. We resumed the
treatment of overall shape necrosis in 90%of cases, and significant
improvement of signs and symptoms in 10%. We conclude that
the combined use of surgery to other therapies may be indicated




